Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study.

Costa Clemens SA, Jepson B, Bhorat QE, Ahmad A, Akhund T, Aley PK, Bansal H, Bibi S, Kelly EJ, Khan M, Lambe T, Lombaard JJ, Matthews S, Pipolo Milan E, Olsson U, Ramasamy MN, Moura de Oliveira Paiva MS, Seegobin S, Shoemaker K, Szylak A, Villafana T, Pollard AJ, Green JA, AZD2816 Study Group

Open source

DOI: 10.1016/s2666-5247(24)00078-8
Published: 2024 Aug
Container: The Lancet. Microbe
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s2666-5247-24-00078-8,
  title = {Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study.},
  author = {Costa Clemens SA and Jepson B and Bhorat QE and Ahmad A and Akhund T and Aley PK and Bansal H and Bibi S and Kelly EJ and Khan M and Lambe T and Lombaard JJ and Matthews S and Pipolo Milan E and Olsson U and Ramasamy MN and Moura de Oliveira Paiva MS and Seegobin S and Shoemaker K and Szylak A and Villafana T and Pollard AJ and Green JA and AZD2816 Study Group},
  year = {2024},
  journal = {The Lancet. Microbe},
  doi = {10.1016/s2666-5247(24)00078-8},
  url = {https://doi.org/10.1016/s2666-5247(24)00078-8}
}

RIS

TY  - JOUR
TI  - Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study.
AU  - Costa Clemens SA
AU  - Jepson B
AU  - Bhorat QE
AU  - Ahmad A
AU  - Akhund T
AU  - Aley PK
AU  - Bansal H
AU  - Bibi S
AU  - Kelly EJ
AU  - Khan M
AU  - Lambe T
AU  - Lombaard JJ
AU  - Matthews S
AU  - Pipolo Milan E
AU  - Olsson U
AU  - Ramasamy MN
AU  - Moura de Oliveira Paiva MS
AU  - Seegobin S
AU  - Shoemaker K
AU  - Szylak A
AU  - Villafana T
AU  - Pollard AJ
AU  - Green JA
AU  - AZD2816 Study Group
PY  - 2024
JO  - The Lancet. Microbe
DO  - 10.1016/s2666-5247(24)00078-8
UR  - https://doi.org/10.1016/s2666-5247(24)00078-8
ER  -

APA

SA, C. C., B, J., QE, B., A, A., T, A., PK, A., H, B., S, B., EJ, K., M, K., T, L., JJ, L., S, M., E, P. M., U, O., MN, R., MS, M. D. O. P., S, S., K, S., A, S., T, V., AJ, P., JA, G., & Group, A. S. (2024). Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study.. The Lancet. Microbe. https://doi.org/10.1016/s2666-5247(24)00078-8

Source records

pubmed · retrieved 2026-09-27T01:38:32.223Z
europe-pmc · retrieved 2026-09-27T01:38:32.240Z